Skip to main content
Erschienen in: Molecular Cancer 1/2023

Open Access 01.12.2023 | Research

circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma

verfasst von: Liangliang Xu, Peng Wang, Li Li, Lian Li, Yang Huang, Yanfang Zhang, Xiaobo Zheng, Pengsheng Yi, Ming Zhang, Mingqing Xu

Erschienen in: Molecular Cancer | Ausgabe 1/2023

Abstract

Background

Vascular invasion is a major route for intrahepatic and distant metastasis in hepatocellular carcinoma (HCC) and is a strong negative prognostic factor. Circular RNAs (circRNAs) play important roles in tumorigenesis and metastasis. However, the regulatory functions and underlying mechanisms of circRNAs in the development of vascular invasion in HCC are largely unknown.

Methods

High throughput sequencing was used to screen dysregulated circRNAs in portal vein tumor thrombosis (PVTT) tissues. The biological functions of candidate circRNAs in the migration, vascular invasion, and metastasis of HCC cells were examined in vitro and in vivo. To explore the underlying mechanisms, RNA sequencing, MS2-tagged RNA affinity purification, mass spectrometry, and RNA immunoprecipitation assays were performed.

Results

circRNA sequencing followed by quantitative real-time PCR (qRT-PCR) revealed that circRNA pleckstrin and Sect. 7 domain containing 3 (circPSD3) was significantly downregulated in PVTT tissues. Decreased circPSD3 expression in HCC tissues was associated with unfavourable characteristics and predicted poor prognosis in HCC. TAR DNA-binding protein 43 (TDP43) inhibited the biogenesis of circPSD3 by interacting with the downstream intron of pre-PSD3. circPSD3 inhibited the intrahepatic vascular invasion and metastasis of HCC cells in vitro and in vivo. Serpin family B member 2 (SERPINB2), an endogenous bona fide inhibitor of the urokinase-type plasminogen activator (uPA) system, is the downstream target of circPSD3. Mechanistically, circPSD3 interacts with histone deacetylase 1 (HDAC1) to sequester it in the cytoplasm, attenuating the inhibitory effect of HDAC1 on the transcription of SERPINB2. In vitro and in vivo studies demonstrated that circPSD3 is a promising inhibitor of the uPA system.

Conclusions

circPSD3 is an essential regulator of vascular invasion and metastasis in HCC and may serve as a prognostic biomarker and therapeutic target.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12943-023-01882-z.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AGO2
argonaute RISC catalytic component 2
AS
alternative splicing
BM
basement membrane
CCK-8
counting kit-8
circRNA
circular RNA
DMEM
dulbecco’s modified Eagle medium
dsRNA
double-stranded RNA
ECM
extracellular matrix
EMT
epithelial-mesenchymal transition
FBS
fetal bovine serum
FISH
Fluorescence in situ hybridization
GFP
Green fluorescent protein
HBV
hepatitis B virus
HCV
hepatitis C virus
HCC
hepatocellular carcinoma
HDAC1
histone deacetylase 1
HE
hematoxylin and Eosin
hnRNP L
heterogeneous nuclear ribonucleoparticles L
IF
immunofluorescence
IHC
immunohistochemistry
IRES
internal ribosome entry site
LC-MS/MS
Liquid chromatography-tandem mass spectrometry
LDLR
low-density lipoprotein receptor
LncRNAs
long non-coding RNAs
LRP
LDL-related protein
MAPK
mitogen activated kinase-like protein
miRNA
micro RNA
MMP
matrix metalloproteinase
MVI
microvascular invasion
NLS
nuclear localization signal
ORF
open reading frame
PI3K
phosphatidylinositol 3-kinase
PAI-1
plasminogen activator inhibitor-1
PAI-2
plasminogen activator inhibitor-1
PTC
papillary thyroid cancer
PVTT
portal vein tumor thrombosis
qRT-PCR
quantitative real-time PCR
RBP
RNA binding protein
RIP
RNA immunoprecipitation
SERPINB2
serpin family B member 2
SERPINB10
serpin family B member 10
TDP43
TAR DNA binding protein
TNM
tumor-node-metastasis
TRAP
MS2-tagged RNA affinity purification
ULA
ultralow attachment
uPA
urokinase-type plasminogen activator
uPAR
plasminogen activator, urokinase receptor
VLDLR
very-low-density lipoprotein receptor
tPA
tissue-type plasminogen activator

Introduction

Hepatocellular carcinoma (HCC) is the most common histological subtype of primary liver cancer with high incidence and poor prognosis [1]. By the year 2025, liver cancer is projected to impact over 1 million individuals annually [2]. Hepatitis B virus (HBV) infection is the leading risk factor for the development of HCC, contributing to approximately 50% of cases [3]. Due to the achievement of sustained virological response (SVR) through the use of antiviral drugs, the risk associated with hepatitis C virus (HCV) infection has markedly declined [4]. Nevertheless, patients with cirrhosis remain at a heightened risk for the development of HCC even after HCV clearance. Additionally, non-alcoholic steatohepatitis (NASH), which is linked to metabolic syndrome or diabetes mellitus, is emerging as the rapidly growing cause of HCC, particularly in Western countries [5]. Metastasis is a defining characteristic of cancer [6]. HCC tends to invade the vascular system to form microvascular invasion (MVI) or portal vein tumor thrombosis (PVTT) [7]. Vascular invasion is a major route for intrahepatic and distant metastasis in HCC and is a strong negative prognostic factor [8]. PVTT is present in 10–60% of patients at the time of initial diagnosis of HCC [9]. Most treatment guidelines classify patients with PVTT as advanced stage with limited treatment options [2]. The median survival time of patients with PVTT treated with supportive care only is just 2–4 months [10]. Except for a small number of patients with simultaneously resectable HCC and PVTT who may benefit from surgery, the outcomes of non-surgical treatment for PVTT are unsatisfactory [11]. Hence, better understanding of the molecular mechanisms of vascular invasion is needed to develop more effective therapeutic approaches for PVTT.
Circular RNA (circRNA) is a new class of RNA that is generated by an alternative splicing method called back-splicing [12]. Due to the loop-like structure and because they lack poly(A) tails, circRNAs are resistant to RNase R degradation and are more stable than linear RNAs [13]. circRNAs exert their biological functions through various mechanisms, such as acting as microRNA (miRNA) sponges, interacting with proteins, and translating novel polypeptides [14]. circRNAs broadly exist in various eukaryotes and play important roles in organ development and disease progression, especially tumorigenesis and metastasis [15]. We previously showed that ciRS-7 is an independent predictor of MVI and circSETD3 inhibits the proliferation of HCC cells by sponging miR-421 [16, 17]. Hu et al. [18] identified circASAP1 as a key regulator of metastasis that may serve as a prognostic biomarker based on circRNA sequencing (circRNA-seq) of patients with HCC and postoperative pulmonary metastases. However, circRNAs that regulate vascular invasion in HCC are unknown.
Given that MVI is only observed under a microscope during pathological diagnosis, studies on MVI tissues are difficult [19]. Unlike MVI, PVTT can be detected by radiological examination and staged according to the site of thrombosis [20]. As patients with simultaneously resectable HCC and PVTT can derive a survival benefit from surgery [8], paired HCC and PVTT tissues harvested during surgery provide a valuable opportunity to study the mechanisms involved in the vascular invasion and metastasis of HCC. RNA sequencing (RNA-seq) has identified numerous dysregulated messenger RNAs (mRNAs) [21], miRNAs [22], and long non-coding RNAs (lncRNAs) [23] in PVTT, some of which have been shown to play an important role in HCC metastasis. In this study, using high throughput circRNA-seq, we showed that circRNA pleckstrin and Sect. 7 domain containing 3 (circPSD3) (derived from exons 13 and 14 of PSD3; circBase ID: hsa_circ_0136098) was significantly downregulated in PVTT tissues. Mechanistically, circPSD3 inhibited the migration and invasion of HCC cells in a urokinase-type plasminogen activator (uPA) system-dependent manner.

Materials and methods

HCC samples

In total, 159 HCC samples were obtained from the West China Biobanks, Department of Clinical Research Management, West China Hospital, Sichuan University. Nineteen patients had paired PVTT tissues and 48 patients had paired non-cancerous liver tissues. All patients underwent radical resection between 2016 and 2018. None of the patients received other preoperative anticancer treatments. The study was approved by the Biomedical Ethics Committee of West China Hospital (Ethic approval ID: 2022(1685)). Written informed consent was obtained from each patient.

circRNA-seq

Five PVTT and matched HCC tissues were selected for RNase R-treated circRNA-seq (Novogene, Beijing, China). Briefly, 5 µg of high-quality RNA per sample was used as input material. Ribosomal and linear RNAs were removed before library preparation. circRNAs were identified using find_circ and CIRI. The R package “DESeq2” (version 2.15.13) was employed to screen differentially expressed circRNAs between PVTT and matched HCC tissues. circRNAs with |log2(fold-change)| >2.5 and FDR < 0.05 were considered to be differentially expressed.

RNA-seq with unique molecular identifiers (UMIs)

To determine downstream targets and pathways of circPSD3, RNA-seq was performed using UMIs (Seqhealth Technology Co. Ltd., Wuhan, China). Briefly, 2 µg of total RNA extracted from HCC-LM9 cells stably transfected with circPSD3 overexpression or control lentivirus was used for stranded RNA-seq library preparation (Catalogue #DR08502; KC-Digital Stranded mRNA Library Prep Kit for Illumina, Seqhealth Technology Co. Ltd.), following the manufacturer’s instructions. The kit eliminates duplication bias in PCR and sequencing steps by using the UMIs of eight random bases to label the pre-amplified cDNA molecules. Library products corresponding to 200–500 bps were enriched, quantified, and sequenced on a NovaSeq 6000 sequencer (PE150 model) (Illumina, San Diego, CA, USA). Raw sequencing data were filtered using Trimmomatic (version 0.36). Clean reads were further treated with in-house scripts to eliminate duplication bias introduced in library preparation and sequencing. TopHat2 (version 2.0.13) was used to align de-duplicated reads to the reference genome (GRCh38/hg38). The R package “DESeq2” (version 2.15.13) was used to identify differentially expressed genes between groups. Genes with |log2(fold-change)| >1 and FDR < 0.05 were considered to be differentially expressed. The molecular functions and pathways of dysregulated genes were analysed in KOBAS 2.0.

Cell culture and transfection

Human HCC cell lines (HCC-LM9 and SK-Hep-1) cells were maintained in Dulbecco’s modified Eagle medium/high-glucose medium (HyClone, Logan, UT, USA) supplemented with 10% foetal bovine serum (FBS) (PAN-Biotek, Aidenbach, Bavaria) and antibiotics (1% penicillin/streptomycin; HyClone) in a humidified incubator with 5% CO2 at 37ºC.
Small interfering RNAs (siRNAs) targeting circPSD3, TAR DNA-binding protein 43 (TDP43), serpin family B member 2 (SERPINB2), and histone deacetylase 1 (HDAC1) were designed and synthesised by RiboBio (Guangzhou, China). The siRNA sequences are listed in Table S1 (Additional file 1). siRNAs were transfected using GeneMute (SignaGen Laboratories, Rockville, MD, USA), according to the manufacturer’s instructions. The lentiviruses used to express circPSD3 and uPA receptor (uPAR) were constructed by GeneChem (Shanghai, China) and infected following the manufacturer’s protocol.

Quantitative real-time (qRT)-PCR

Genomic DNA (gDNA) was isolated using the PureLink™ Genomic DNA Mini Kit (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions. Total RNA was extracted using TRIzol (Invitrogen Life Technologies Inc., Germany). Reverse transcription was performed using HiScript III RT SuperMix for qPCR (+ gDNA wiper) Kit (Vazyme Biotech Co. Ltd., Nanjing, China). Nuclear and cytoplasmic fractions were isolated using the PARIS™ Kit (Thermo Fisher Scientific). qRT-PCR was performed in triplicate using 2× ChamQ Universal SYBR qPCR Master Mix (Vazyme Biotech Co. Ltd.) and the CFX Connect Real-Time System (Bio-Rad, Hercules, CA, USA). The primers used in this study are listed in Table S2 (Additional file 1).

Fluorescence in situ hybridisation (FISH)

Cy3-labelled probes were synthesised by RiboBio. FISH was performed using the FISH Kit (RiboBio), according to the manufacturer’s instructions. Images were captured using the A1RþMP Confocal Laser Microscope System (Nikon, Tokyo, Japan). U6 and 18 S ribosomal RNAs (rRNAs) were used as positive controls in the nucleus and cytoplasm, respectively.

Actinomycin D and RNase R treatment assays

circRNA stability was assessed using actinomycin D and RNase R treatment assays. For actinomycin D assay, HCC cells were cultured in medium containing 2 mg/mL actinomycin D. Total RNA was isolated at the indicated time points and subjected to qRT-PCR. For RNase R treatment, 3 µg of total RNA was treated with 10 U RNase R (20 U/µL; Epicenter, Madison, WI, USA) at 37 °C for 45 min, followed by 70 °C for 10 min to deactivate RNase R. Linear and circular RNA degradation was determined by PCR followed by agarose gel electrophoresis.

Western blotting and immunohistochemistry

Western blotting was performed as described previously [17, 24]. The following primary antibodies were used: anti-SERPINB2 (1:1,000) (Proteintech, Wuhan, China), anti-uPAR (1:1,000) (Abcam, Cambridge, UK), anti-uPA (1:1,000) (Abcam), anti-HDAC1 (1:1,000) (Abclonal, Wuhan, China), anti-AGO2 (1:1,000) (Abclonal), anti-GST (1:1,000) (Abcam), anti-FLAG (1:1,000) (Abclonal), and anti-TDP43 (1:1,000) (Proteintech). Immunohistochemistry was performed using antibodies against TDP43 (1:200) (Proteintech), SERPINB2 (1:200) (Proteintech), and uPAR (1:200) (Abcam), as described previously [17, 24].

Immunofluorescence staining

Cells were seeded into a 24-well plate with a coverslip at the bottom of each well. After incubation for 24 h at 37 °C, the cells were fixed with 4% paraformaldehyde for 30 min, permeabilised with 0.2% Triton X-100 for 10 min, and blocked with 3% bovine serum albumin for 1 h. Cells were incubated with specific antibodies at 4 °C overnight and with fluorescence-conjugated secondary antibodies at 37 °C for 1 h. Nuclei were stained with 4’6-diamidino-2-phenylindole (DAPI) for 10 min. After sealing, images were acquired using a confocal laser scanning microscope (Nikon).

Cell viability assay

Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) and colony formation assays. For CCK-8 assay, HCC cells were suspended in 100 µL of medium and seeded into 96-well plates at a density of 2,000 cells/well. After incubation with 10 µL of CCK-8 solution for 1.5 h, absorbance at 450 nm was measured at indicated time points using the Eon Microplate Reader (BioTek, Whiting, VT, USA). For colony formation assay, 1,000 cells were seeded into each well of a 6-well plate. After incubation for 14 days, the colonies were fixed with 4% paraformaldehyde (Solarbio, Beijing, China) and stained with 0.05% crystal violet (Beyotime Biotechnology, Nantong, China). Colonies were photographed and counted. All experiments were performed in triplicate.

Wound healing assay

Confluent monolayer cells in 6-well plates were wounded using a 200 µL pipette tip. After washing with PBS twice, cells were cultured in medium containing 3% FBS. Images were acquired using an inverted microscope (Carl Zeiss, Jena, Germany) at 0 and 48 h after wounding. At least three separate fields were photographed. The relative healed area was calculated using ImageJ (National Institutes of Health, Bethesda, MD, USA) and normalised to 0 h control.

Transwell migration and Matrigel invasion assays

For Transwell migration assay, 3 × 104 HCC cells were suspended in 300 µL of serum-free medium and seeded into the upper chamber (pore size, 8 μm) (Millipore, Billerica, MA, USA). The bottom chamber contained 600 µL of medium containing 10% FBS as a chemoattractant. After 24 h, cells on the lower surface of the upper chamber were fixed with 4% paraformaldehyde, stained with 0.05% crystal violet, and imaged at 100× magnification. At least three random fields were photographed. Migrated cell numbers were counted using Image J. A similar protocol was performed for Matrigel invasion assay, except 30 µL of diluted Matrigel (BD Bioscience, Bedford, MA, USA) was added to the upper chamber before cell seeding.

3D spheroid-based Matrigel invasion assay

Complete growth medium containing 1 × 104 SK-Hep-1 cells (200 µL) was seeded into ultralow attachment 96-well round-bottom plates (Corning, USA) for 3 days, as described previously [2527]. Images were acquired when tumor spheroids were formed (Day 0). Then, 100 µL of plating medium was removed and replaced with the same volume of Matrigel. After Matrigel solidification, 100 µL of complete growth medium was added to each well. After 3 days, images were photographed and analysed using the Celigo cytometer (Nexcelom Bioscience, Lawrence, MA, USA).

RNA immunoprecipitation (RIP) assay

RIP assay was performed using the Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore), according to the manufacturer’s instructions. Briefly, magnetic beads were sequentially incubated with primary antibodies and prepared cell lysates. Enriched RNA was isolated using TRIzol reagent and quantified by qRT-PCR. Immunoglobulin G antibody served as the negative control.

MS2-tagged RNA affinity purification (TRAP) assay

A 2× MS2 stem–loop sequence was inserted at the back-splicing site of circPSD3 (Biosense, Guangzhou, China). The MS2-circPSD3 expression plasmid or negative control plasmid was co-transfected with the GST-MS2 expression plasmid into HCC cells. The cell lysates were incubated with anti-GST-coated magnetic beads (Beyotime Biotechnology) at 4 °C overnight. Enriched RNAs and proteins were collected. RNA was quantified by qRT-PCR. Proteins were quantified by liquid chromatography–tandem mass spectrometry (LC-MS/MS) (OEBiotech, Shanghai, China) and validated by western blotting.

Dual-luciferase reporter assay

A dual-luciferase reporter plasmid was constructed as a vector containing Renilla luciferase (Rluc) and firefly luciferase (Luc) (VectorBuilder, Guangzhou, China). The predicted internal ribosome entry site (IRES) of circPSD3 or mutant sequences was subcloned into the promoter region of Luc. The plasmid was transfected into HEK-293T cells using Lipo6000 Transfection Reagent (Beyotime Biotechnology), following the manufacturer’s instructions. After incubation for 48 h, Rluc and Luc activity was determined using the Duo-Lite Luciferase Assay System (Vazyme Biotech Co. Ltd.). Results are presented as the ratio of Luc to Rluc.

Animal metastasis models

Male BALB/c nude mice (5–6 weeks old) were purchased from HFK Bioscience (Beijing, China) and maintained under specific pathogen-free conditions. All animal experiments were approved by the Animal Care Committee of Sichuan University (Ethic approval ID: 20,220,224,052). To establish a lung metastasis model, HCC cells were injected into the tail vein of nude mice. Five weeks later, the mice were anaesthetised. Resected lung specimens were stained with haematoxylin and eosin (H&E). To establish an intrahepatic metastasis model, 2 × 106 stably transfected cells were injected into the liver of nude mice. Six weeks later, liver lobes containing tumors were harvested and subjected to H&E staining. Serial sectioning of liver tissues was performed to confirm vascular invasion. Pathological images were acquired using a Whole Slide Image Scanner (Unic Technologies Inc., Beijing, China). The number of metastatic nodules and vascular invasion were determined by two independent investigators. At least five mice were included in each group. All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals.

Statistical analysis

Statistical analyses were conducted using SPSS (version 21.0) (IBM Corp., Armonk, NY, USA), GraphPad Prism (version 8.0) (GraphPad Software, La Jolla, CA, USA), and R (version 3.5.0) (The R Foundation, Vienna, Austria; http://​www.​r-project.​org/​). Continuous variables were expressed as mean ± SD and compared using Student’s t-test. Categorical variables were expressed as numbers and percentages and compared using the chi-square test or Fisher’s exact test, as appropriate. Correlations were determined using Pearson’s correlation coefficients. The optimal cut-off value for circPSD3 expression in HCC tissues was determined using X-tile software. Survival curves were plotted using the Kaplan–Meier method and compared using the log-rank test. All statistical tests were two-tailed. A p-value < 0.05 was considered statistically significant.

Results

CircPSD3 is a potential regulator of PVTT formation

To screen for circRNAs involved in vascular invasion in HCC, we performed circRNA-seq on five paired PVTT and HCC tissues. A total of 13,238 circRNAs (distributed across all chromosomes) were detected (Additional file 1: Figure S1A; Additional file 2: Table S3). Among them, 8,523 were annotated in circBase. The remaining 4,715 were considered novel. Most circRNAs ranged from 200 to 600 bp in length and were derived from exons (Additional file 1: Figure S1B, C). Based on the criteria of |log2(fold-change)| >2.5 and p < 0.05, 100 differentially expressed circRNAs were identified, including 46 that were significantly upregulated and 54 that were significantly downregulated in PVTT tissues (Fig. 1A, B). However, None of the differentially expressed circRNAs had an adjusted p-value < 0.05, indicating high heterogeneity among PVTT tissues (Additional file 3: Table S4), consistent with lncRNA-seq [23].
To further ascertain circRNAs associated with vascular invasion, eight of the most significantly dysregulated circRNAs (four upregulated and four downregulated) were selected and validated by qRT-PCR in 19 paired PVTT and HCC tissues (Fig. 1C). The melt curves of qRT-PCR and agarose gel electrophoresis of PCR products demonstrated the specificity of divergent primers against these circRNAs (Additional file 1: Fig. S1D and E). Sanger sequencing further confirmed that these primers amplified the target circRNAs (Additional file 1: Fig. S1F). Our results show that only circPSD3 was significantly downregulated in PVTT tissues compared with matched HCC tissues (Fig. 1C). circPSD3 was also the most significantly downregulated circRNA in circRNA-seq.
Next, we performed qRT-PCR to measure the expression levels of circPSD3 in another cohort comprising 140 human HCC tissues, 48 of which had paired non-cancerous tissues. As expected, circPSD3 was significantly downregulated in HCC tissues compared with non-cancerous tissues (Fig. 1D). The expression levels of circPSD3 in the MVI group were significantly lower than those in the non-MVI group (Fig. 1E), indicating that circPSD3 may be associated with vascular invasion. The optimal cut-off value of circPSD3 in HCC tissues was 0.465 for both overall survival and recurrence. Using this cut-off value, patients were divided into a low circPSD3 group (n = 61) and a high circPSD3 group (n = 79). Kaplan–Meier curves showed that decreased circPSD3 expression was associated with significantly poorer recurrence-free survival and overall survival in patients with HCC (Fig. 1F, G). The expression levels of circPSD3 in HCC tissues were associated with various clinicopathological characteristics, including elevated alpha-fetoprotein levels, multiple tumors, and the presence of MVI (Additional file 1: Table S5). Therefore, circPSD3 was selected as a candidate circRNA for the regulation of vascular invasion and metastasis in HCC and investigated in depth.
As shown in Fig. 1H, circPSD3 was back-spliced by exons 13 and 14 of PSD3 located on chromosome 8 with a length of 1,504 nucleotides. To confirm the circular property of circPSD3, a series of experiments were performed. First, the back-splice junction site of circPSD3 was confirmed by Sanger sequencing in HCC cells (Fig. 1H). Second, circPSD3 could only be amplified from cDNA and not from gDNA using divergent primers, whereas the corresponding linear transcript could be amplified from both cDNA and gDNA using convergent primers, with GAPDH as the reference gene, indicating that circPSD3 was generated by head-to-tail splicing rather than by trans-splicing or genomic rearrangement (Fig. 1I). Third, actinomycin D and RNase R treatment assays demonstrated that circPSD3 was more stable than linear PSD3 (Fig. 1J, K). Finally, nuclear and cytoplasmic RNA separation and FISH assays showed that circPSD3 was preferentially located in the cytoplasm of HCC cells (Fig. 1L, M).

TDP43 inhibits the biogenesis of circPSD3 in HCC

Many RNA-binding proteins regulate the biogenesis of circRNAs by adhering to up or downstream introns flanking the back-splicing sites [2830]. Using the online CircInteractome tool (https://​circinteractome.​nia.​nih.​gov/​rna_​ binding_protein.html), we found three putative binding sites of TDP43 in the downstream intron of circPSD3 pre-mRNA (Fig. 2A). TDP43 mediates several aspects of RNA metabolism, including RNA transcription, alternative splicing, and mRNA stabilisation, by interacting with UG repeats [31]. Herein, a (UG)11 repeat was identified in the third putative binding site of circPSD3 (Fig. 2B). To confirm the interaction between TDP43 and circPSD3 pre-mRNA, five primer pairs (A–E) were designed to target intron 12, the main body of circPSD3, and three TDP43-binding sites in intron 14, respectively (Fig. 2B). Next, a RIP assay was performed using an anti-TDP43 antibody. As expected, TDP43 only enriched sequences targeted by primer E (Fig. 2C), indicating that TDP43 formed a protein–RNA complex via the putative binding sites in circPSD3 pre-mRNA. Studies have shown that TDP43 is upregulated in HCC tissues and facilitates the degradation of HCC [3234]. In this study, the mRNA level of TDP43 was measured in 48 paired HCC samples. We found that circPSD3 was significantly upregulated in HCC tissues compared with non-cancerous tissues (Fig. 2D). This result was strengthened by western blotting in six paired HCC tissues (Fig. 2E). In a patient with HCC and PVTT, immunohistochemical staining showed that the density of TDP43 increased from non-cancerous to HCC and to PVTT tissues (Fig. 2F), demonstrating the stimulatory effect of TDP43 on vascular invasion in HCC. Pearson correlation analysis revealed that the expression of TDP43 in HCC tissues was negatively correlated with circPSD3 (Fig. 2G). TDP43 depletion significantly increased circPSD3 expression in HCC cells (Fig. 2H–J). Taken together, these results suggest that TDP43 suppresses circPSD3 biogenesis and that circPSD3 may mediate the regulatory effect of TDP43 on the invasion and metastasis of HCC cells.

circPSD3 inhibits the migration and invasion of HCC cells in vitro

To explore the effect of circPSD3 on HCC progression, the expression of circPSD3 was artificially changed using an overexpression lentivirus and two shRNA lentiviruses targeting the back-splicing site of circPSD3. After transfection, > 90% of cells expressed green fluorescent protein (Additional file 1: Fig. S2). qRT-PCR showed that circPSD3 was successfully overexpressed or knocked down in HCC cells with no effect on linear PSD3 (Fig. 3A–D). HCC cell migration was significantly reduced in response to circPSD3 overexpression, and was significantly enhanced in response to circPSD3 knockdown, in the wound healing assays (Fig. 3E, F). HCC cell migration and invasion were diminished by circPSD3 overexpression, and enhanced by circPSD3 knockdown, in the Transwell assays (Fig. 3G, H). Moreover, a 3D spheroid-based invasion assay was performed to mimic HCC cell invasion in vivo. Stable overexpression of circPSD3 significantly reduced the invasion area and the number of protrusions, whereas circPSD3 depletion significantly increased the invasion area and the number of protrusions in SK-Hep-1 cells (Fig. 3I, J). Nevertheless, CCK-8 and colony formation assays showed that circPSD3 had no effect on the proliferation of HCC cells (Additional file 1: Fig. S3A–E). Taken together, these results suggest an inhibitory effect of circPSD3 on HCC cell migration and invasion, but not growth.

circPSD3 suppresses distant metastasis, intrahepatic metastasis, and vascular invasion of HCC cells

To strengthen the findings of the in vitro studies, pulmonary metastasis and liver orthotopic implantation models were constructed. Whole-slide scans of H&E-stained sections showed that overexpression of circPSD3 significantly reduced the number of lung metastatic lesions (Fig. 4A). Overexpression of circPSD3 also significantly reduced intrahepatic metastasis (Fig. 4B). To evaluate the effect of circPSD3 on intrahepatic vascular invasion, serial sectioning of liver tissues and H&E staining were performed. The results showed that overexpression of circPSD3 significantly reduced the vascular invasion ability of HCC cells (Fig. 4C). Conversely, circPSD3 knockdown significantly increased lung metastasis, intrahepatic metastasis, and intrahepatic vascular invasion (Fig. 4D–F). Taken together, these results suggest that circPSD3 plays an important role in inhibiting the vascular invasion and metastasis of HCC cells and is a promising therapeutic target.

circPSD3 regulates the uPA system

To explore the underlying regulatory mechanism of circPSD3 in hepatocellular carcinoma (HCC) metastasis, we conducted RNA-seq analysis on HCC-LM9 cells that were stably transfected with either circPSD3 overexpression or control lentivirus. This approach aimed to identify potential genes and signaling pathways that are influenced by circPSD3 in HCC cells. Based on a differential filtering criteria of (|log2(fold change)|> 1 and p < 0.05), a total of 240 dysregulated genes were identified by RNA-seq, including 42 significantly upregulated and 178 significantly downregulated genes in the circPSD3 overexpression group (Fig. 5A, Additional file 1: Fig. S4A, and Additional file 4: Table S6). Enrichment analysis showed that these aberrantly expressed genes were involved in multiple tumor-related pathways, including the PI3K-AKT, MAPK, focal adhesion, and extracellular matrix (ECM)-receptor interaction pathways (Additional file 1: Fig. S4B, C). qRT-PCR validation of the top five significantly up and downregulated genes was performed in HCC-LM9 and SK-Hep-1 cells. As shown in Fig. 5B, C, the qRT-PCR results were highly consistent with those of RNA-seq. Among these top changed genes, SERPINB2 was the most upregulated gene after circPSD3 overexpression. SERPINB2 is an endogenous inhibitor of the uPA system. The uPA system plays a pivotal role in the degradation of the ECM and basement membrane during cell invasion. SERPINB2 interacts with uPA to induce endocytosis of uPA–uPAR complexes in a low-density lipoprotein receptor (LDLR)-dependent manner [35, 36]. To further confirm the regulatory role of circPSD3 in the expression of SERPINB2, the expression levels of SERPINB2 were measured in HCC cells with stable knockdown of circPSD3. The results showed that circPSD3 depletion effectively reduced SERPINB2 expression in HCC cells (Fig. 5D, E). The regulatory effects of circPSD3 on SERPINB2 and other components of the uPA system (uPA and uPAR) were examined by western blotting (Fig. 5F). These results suggest that SERPINB2 and its regulated uPA system are downstream targets of circPSD3.
To investigate the effect of the uPA system on HCC progression, the mRNA levels of SERPINB2, uPA, and uPAR were measured by qRT-PCR in 48 paired HCC and non-cancerous tissues. SERPINB2 was significantly downregulated, and uPA and uPAR were significantly upregulated, in HCC tissues (Fig. 5G–I), consistent with previous studies [3740]. Pearson correlation analysis showed that SERPINB2 expression was positively associated with circPSD3 in HCC tissues (Fig. 5J), strengthening the regulatory relationship between circPSD3 and SERPINB2. Immunohistochemical staining of two patients with HCC and PVTT showed that the protein levels of SERPINB2 gradually decreased from non-cancerous to HCC and to PVTT tissues, whereas an inverse trend was observed for uPAR (Fig. 5K), indicating the potential of the uPA system to promote vascular invasion in HCC. In vitro studies showed that SERPINB2 knockdown significantly promoted the migration and invasion of HCC cells (Additional file 1: Fig. S5A–E). Rescue experiments showed that SERPINB2 depletion abrogated the inhibitory effect of circPSD3 on cell migration and invasion (Additional file 1: Fig. S5F, G). Similarly, WX-671, an inhibitor of uPA system, significantly reduced the cell migration and invasion that were induced by circPSD3 knockdown (Fig. 5L, M). Taken together, these results suggest that SERPINB2 and its regulated uPA system mediate the inhibitory effect of circPSD3 on the migration and invasion of HCC cells.

circPSD3 directly interacts with HDAC1

Next, we investigated the mechanism of circPSD3 regulation of SERPINB2. As circPSD3 is predominantly localised to the cytoplasm of HCC cells, we speculated that circPSD3 may act as a miRNA sponge. However, RIP analysis showed that the AGO2 antibody did not enrich circPSD3, with ciRS-7 serving as a positive control (Additional file 1: Fig. S6). Therefore, we ruled out the possibility of circPSD3 functioning as a miRNA sponge.
Encoding functional peptides is a novel mechanism for some circRNAs, and open reading frame (ORF) and internal IRES are necessary for the translation of circRNAs. The ORF and IRES of circPSD3 were predicted using the circRNADb database (Additional file 1: Fig. S7A), suggesting that circPSD3 has the potential to encode a protein. The dual-luciferase assay showed that the IRES of circPSD3 effectively initiates the translation of luciferase mRNA compared with mutated sequences (Additional file 1: Fig. S7B). We inserted a FLAG coding sequence before the stop codon of the putative ORF of circPSD3 and detected a FLAG-labelled protein in HEK-293T cells (Additional file 1: Fig. S7C), implying that the ORF of circPSD3 may act as a template for translation. To confirm the encoding ability of circPSD3 in the circular isoform, we generated two highly specific antibodies against the 19–35 and 362–488 amino acid sequences of the ORF of circPSD3, which were designed to recognise proteins encoded by circPSD3 (Additional file 1: Fig. S7D). FLAG-tagged ORF and circPSD3 overexpression vectors were successfully transfected into HCC cells (Additional file 1: Fig. S7E). However, western blotting only showed a strong band in HCC cells transfected with the FLAG-tagged ORF vector and not the circPSD3 overexpression vector (Additional file 1: Fig. S7F), suggesting that circPSD3 is a non-coding RNA.
Protein interactions also play an important role in circRNA function. In previous studies, circRNA-interacting proteins were identified by RNA-pulldown assays using a biotin-labelled probe targeting the back-splicing site of circRNA [41, 42]. However, owing to the high GC content (55%) at the back-splicing site, it was difficult to design a probe targeting circPSD3. Instead, we used an MS2-tagged TRAP assay to identify proteins interacting with circPSD3. The circPSD3-MS2 and GST-MS2 vectors were co-transfected into HCC-LM9 cells. Potential circPSD3-binding proteins were detecting using GST antibody-coated magnetic beads (Fig. 6A). qRT-PCR was performed to confirm the upregulation of GST and circPSD3 in HCC cells transfected with these vectors. MS2 sequences were detected by denatured agarose gel electrophoresis and Sanger sequencing (Additional file 1: Fig. S8A, B). Silver staining revealed a specific protein band at ~ 70 KD in the circPSD3-MS2 group (Additional file 1: Fig. S8C). Subsequent LC-MS/MS identified 145 proteins that were uniquely enriched in the circPSD3-MS2 group, 16 of which had more than three unique peptide sequences (Fig. 6C and Additional file 5: Table S7). As expected, LC-MS/MS analysis did not reveal any interaction between circPSD3 and AGO2 (Additional file 1: Fig. S6), consistent with the RIP results.
Given that circPSD3 exerts regulatory control over the expression of SERPINB2, affecting both its mRNA and protein levels. Additionally, RNA-seq results also showed that circPSD3 significantly upregulates the mRNA level of SERPINB10, a gene located downstream of SERPINB2 on chromosome 18 (Additional file 1: Fig. S8D). Therefore, we speculated that circPSD3 interacts with a protein that regulates the transcription of SERPINB2. Among circPSD3-MS2-enriched proteins, HDAC1 is a member of the family of histone deacetylases that are involved in transcriptional repression through histone deacetylation (Fig. 6D; Additional file 1: Fig. S8E and F; and Additional file 5: Table S7) [43]. The TRAP assay and western blotting analysis further confirmed the interaction between circPSD3 and HDAC1 (Fig. 6E). The RIP assay also showed that circPSD3 was precipitated by HDAC1 in HCC cells (Fig. 6F). FISH and IF analysis visualised the co-localisation of endogenous circPSD3 and HDAC1 in the cytoplasm of HCC cells (Fig. 6G). Previous studies reported that HDAC1 binds to the promoter of SERPINB2 and regulates the expression of SERPINB2 [44, 45]. Our results also showed that HDAC1 knockdown significantly upregulated the expression of SERPINB2 in HCC cells (Fig. 6H), with corresponding changes in the protein levels of uPA and uPAR (Additional file 1: Fig. S8G). Hence, we selected HDAC1 as a candidate circPSD3-interacting protein. Subsequently, we sought to determine which region of HDAC1 was responsible for its interaction with circPSD3. According to catRAPID, the 376–427 amino acid sequence of HDAC1 was the most likely site to mediate the interaction between HDAC1 and circPSD3 (Additional file 1: Table S8). To test this hypothesis, wild-type and a panel of truncated HDAC1 mutant plasmids were constructed, each of which was tagged with three copies of FLAG (3 × FLAG) at the NH2 terminus (Fig. 6I). These vectors were successfully expressed in HEK-293T cells (Fig. 6J). RIP assays showed that deletion of the 376–427 amino acid sequence of HDAC1 abolished the interaction between HDAC1 and circPSD3 (Fig. 6K).

circPSD3 inhibits nuclear translocation of HDAC1

However, western blotting analysis revealed that circPSD3 did not have any impact on the protein levels of HDAC1 (Additional file 1: Fig. S8H). Meanwhile, no modifying proteins were identified by TRAP assay. Using DeepLoc-1.0 software (https://​services.​healthtech.​dtu.​dk/​services/​DeepLoc-1.​0/​), we found that the nuclear localisation signal of HDAC1 partially overlaps with the putative binding site of circPSD3 (Fig. 6L). Therefore, we speculated that preferential localisation of circPSD3 in the cytoplasm may retain HDAC1 in the cytoplasm, thereby reducing the inhibitory effect of HDAC1 on the transcription of SERPINB2. Consistent with this hypothesis, immunofluorescence and nuclear and cytoplasmic fractionation assays showed that circPSD3 knockdown significantly reduced the protein levels of HDAC1 in the cytoplasm of HCC cells (Fig. 6M, N).
Next, wound healing and Transwell assays were performed to determine whether HDAC1 mediates circPSD3 expression during HCC metastasis. HDAC1 depletion significantly suppressed the migration and invasion of HCC cells (Additional file 1: Fig. S9A, B). Co-transfection of HDAC1-targeted siRNA significantly reduced the cell migration and invasion that were enhanced by knocking down circPSD3 (Additional file 1: Fig. S9C, D). These results suggest that HDAC1 mediates the inhibitory effect of circPSD3 on the migration and invasion of HCC cells via interacting with circPSD3.

circPSD3 provides a novel strategy to inhibit the uPA system

Given the potency of the uPA system in promoting invasion and metastasis in a wide variety of malignancies, targeting the uPA system is a potential strategy for the treatment of cancer [46]. circRNAs are gradually being recognised as promising treatment agents by virtue of their high stability, low molecular weight, and low immunogenicity [13]. This study has shown that SERPINB2 is a target of circPSD3, suggesting that artificial overexpression of circPSD3 may be a novel approach to inhibit the uPA system. To test this hypothesis, the expression of uPAR was upregulated in HCC cells to mimic an activated uPA system (Fig. 7A). Wound healing and Transwell assays showed that uPAR overexpression significantly increased the migration and invasion of HCC cells (Fig. 7B, C), and this effect was abolished by circPSD3 overexpression (Fig. 7D, E). These results were further strengthened by the pulmonary metastasis and liver orthotopic implantation models, in which co-overexpression of circPSD3 significantly attenuated the lung metastatic lesions and intrahepatic metastatic nodules induced by upregulating uPAR (Fig. 7F, G). However, the inhibitory effect of in vitro synthesised circPSD3 on vascular invasion and metastasis in HCC requires further investigation.

Discussion

Vascular invasion is a well-known prognostic factor in HCC that is used to guide classification and treatment. Until now, the mechanisms of vascular invasion have remained largely unknown, and treatment options are limited. In this study, using circRNA-seq and qRT-PCR validation, we showed that circPSD3 is downregulated in PVTT tissues. Decreased circPSD3 expression in HCC tissues is an indicator of MVI and is a predictor of poor prognosis in patients undergoing partial hepatectomy. Artificial regulation of circPSD3 affects the migration and invasion of HCC cells, which was demonstrated by a series of in vitro and in vivo experiments. Mechanistic investigations revealed that SERPINB2 is the downstream target of circPSD3. SERPINB2, an endogenous inhibitor of the uPA system, mediates the inhibitory effect of circPSD3 on the invasion and metastasis of HCC cells. To our knowledge, this is the first study to show the relationship between circRNA and vascular invasion, as well as the uPA system.
Theoretically, a single host gene can produce a panel of circRNAs that have different expression patterns and biological functions, due to disparate compositions. The circRNAs produced by PSD3 pre-mRNA have attracted attention in cancer and other diseases. Consistent with our study, a PSD3-derived circRNA was found to be significantly downregulated in ccRCC tissues and was associated with metastasis in patients with ccRCC. circPSD3 overexpression suppressed cell migration and invasion and epithelial–mesenchymal transition in vitro, and inhibited pulmonary metastasis in vivo, in a miR-25-3p/FBXW7-dependent manner [47]. Another PSD3-derived circRNA was found to be significantly upregulated in papillary thyroid cancer tissues and cell lines and was positively associated with a larger tumor size, TNM stage, and lymph node metastasis. circPSD3 knockdown suppressed papillary thyroid cancer cell proliferation and invasion by enhancing the inhibitory effect of miR-7-5p on the expression of METTL7B [48]. The pathological functions of different PSD3-derived circRNAs have also been investigated in hepatic fibrosis [49] and hepatitis C virus (HCV) infection [50]. These researches suggest that PSD3-derived circRNAs play important roles in multiple disease contexts. In-depth investigations of these circRNAs will be meaningful in identifying novel therapeutic targets.
Emerging publications have reported that the biogenesis of circRNAs can be regulated by multiple RBPs. Such as QKI regulates the formation of cSMARCA5 [51], FUS regulates the biogenesis of circCNOT6L [52], and EIF4A3 regulates circMMP9 [53] and circTOLLIP [54] expression. In current study, we demonstrated that TDP43 is an essential regulator on the biogenesis of circPSD3. To our knowledge, this is the first study to reveal the regulating effect of TDP43 on the biogenesis of circRNAs. TDP43 encoded by the TARDBP gene mediates multiple aspects of RNA metabolism, including RNA transcription, alternative splicing, and mRNA stabilisation [31]. Previous studies have mainly focused on neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease [55]. However, studies have also demonstrated a relationship between TDP43 and a variety of malignancies, such as triple-negative breast cancer [56, 57], lung cancer [58], and melanoma [59]. In HCC, several studies have reported that TDP43 is upregulated in HCC tissues. The interaction between TDP43 and GSK3β mRNA inhibits the translation of GSK3β, thereby activating the Wnt/β-catenin pathway to enhance HCC cell proliferation and metastasis [33]. TDP43 enhances the stability of ABHD2 mRNA by binding to its 3’UTR. Upregulated ABHD2 enhances lipid metabolism and suppresses apoptosis in HCC cells [34]. TDP43 also inhibits the expression of the miR-520 family by interacting with the miR-520 family promoter. The miR-520/PFKP axis mediates TDP43 regulation of glycolysis in HCC cells [32]. Consistent with these findings, our study showed that TDP43 mRNA levels were significantly higher in HCC tissues than in non-cancerous tissues. This result was strengthened by western blotting in six paired HCC tissues and immunohistochemical staining in a patient with HCC and PVTT. TDP43 expression was inversely correlated with the expression of circPSD3 in HCC tissues, and TDP43 knockdown significantly increased the expression of circPSD3 in HCC cells. Considering the inhibitory effect of circPSD3 on invasion and metastasis, we believe that circPSD3 may be another mediator of TDP43 regulation of vascular invasion and distant metastasis in HCC.
Studies have reported that PSD3-derived circRNAs can sequester miRNAs. However, due to differences in sequences among PSD3-derived circRNAs and the undetectable interaction between circPSD3 and AGO2, sponging miRNAs may not be the primary mechanism by which PSD3-derived circRNAs exert their function. Bioinformatics analysis predicted that circPSD3 may encode novel peptides. The function of the IRES in mediating protein translation and the ORF as a template was also confirmed using appropriate vectors. However, upregulated protein level in circPSD3-overexpressing cells was not detected using specific antibodies against two different amino acid sequences of the predicted encoded peptides. circRNAs tend to form short imperfect intramolecular double-stranded RNAs [60, 61] and interact with diverse molecules [13], these all may largely restrict the recognition of ribosome and the extension of peptide chain. Therefore, the research on translation of circRNAs is still initially, and the encoding notion of circNRAs should be strengthened by more high-quality explorations.
TRAP assay revealed numerous proteins that may potentially interact with circPSD3. Among them, HDAC1, is involved in transcriptional repression through histone deacetylation, allowing histones to wrap DNA tightly. To target specific genomic regions, HDAC1 must interact with DNA binding factors (e.g., transcription factors, nuclear receptors, and DNA methyltransferases). In human corneal and conjunctival epithelial cells, HDAC1 binds to the SERPINB2 promoter, together with pRb2/ p130, E2F5, DNMT1, and SUV39H1 [44]. In MCF-7 breast cancer cells, HDAC1 interacts with CPT1A variant 2 (CPT1AV2). CPT1AV2 knockdown upregulates the levels of HDAC1 and alters the expression of multiple cancer-related genes, including the downregulation of SERPINB2 [45]. HDAC1 is significantly upregulated in HCC tissues compared to matched non-cancerous tissues. Elevated HDAC1 expression in HCC tissues is associated with a higher incidence of portal vein invasion, poorer histological differentiation, and a shorter survival time after hepatectomy [62, 63]. HDAC1 plays important roles in the proliferation, differentiation, apoptosis, and metastasis of HCC cells. In a recent study, HDAC1 interacted with HIF-1α to downregulate the expression of FAM99A, thereby inhibiting HCC metastasis and epithelial–mesenchymal transition by negatively regulating miR-92a during hypoxia [64]. Consequently, we selected HDAC1 as a candidate mediator of the regulatory effect of circPSD3 on SERPINB2 expression and HCC metastasis. The interaction between circPSD3 and HDAC1 was demonstrated in a series of experiments. We found that HDAC1 knockdown enhanced the expression of SERPINB2 in HCC cells. Rescue experiments showed that HDAC1 knockdown attenuated the promoting effects of circPSD3 knockdown on the migration and invasion of HCC-LM9 and Sk-Hep-1 cells. These results suggest that HDAC1 is a key mediator of the inhibitory effect of circPSD3 on HCC metastasis. However, circPSD3 did not have any impact on the protein levels of HDAC1. No protein modifying proteins were identified by LC-MS/MS. HDAC1 is localised to both the nucleus and cytoplasm of HCC cells. The nuclear localising signal of HDAC1 is partially overlaps with the putative binding site of circPSD3. Therefore, we speculated that preferential localisation of circPSD3 in the cytoplasm may retain HDAC1 in the cytoplasm, thereby reducing the transcriptional repression effect of HDAC1. This hypothesis was tested by immunofluorescence and nuclear and cytoplasmic fractionation assays. However, the binding sequence on circPSD3 that mediates its interaction with HDAC1, and the detailed mechanism involved in the cytoplasmic retention of HDAC1, require further investigation.
Degradation of the basement membrane and ECM is primarily mediated by plasmin [65] and is essential for cell migration, invasion, and metastasis [6]. Plasmin is produced by the inactive zymogen, plasminogen [66], which is activated by two types of plasminogen activators: the tissue-type plasminogen activator (tPA) and the uPA [66]. tPA preferentially mediates the degradation of intravascular fibrin deposition [67], whereas uPA, uPAR, and two endogenous inhibitors, plasminogen activator inhibitor-1 (PAI-1; also known as SERPINE1) and PAI-2 (also known as SERPINB2), constitute the uPA system [46]. Once bound to uPAR, uPA catalyses the conversion of plasminogen to plasmin, forming an effective proteolytic enzyme system at the cell surface [68, 69]. Plasmin not only degrades components of the ECM, but also promotes ECM degradation by activating latent MMPs and growth factors [70, 71]. The proteolytic activity of uPA can be suppressed by SERPINE1 or SERPINB2 [72, 73]. After uPA inhibition, uPA–PAI complexes facilitate the interaction between uPAR and low-density lipoprotein receptor, thereby stimulating endocytosis of uPA–PAI complexes and partial recycling of uPAR to the cell surface [74]. Generally, SERPINB2 expression in tumor tissues is negatively associated with cancer growth and metastasis. Using immunohistochemistry, Zhou et al. [38] revealed that the proportion of SERPINB2-positive cells in HCC tissues was significantly lower than that in non-cancerous tissues (26.9% vs. 71.8%, respectively). Negative intratumoral staining of SERPINB2 was independently associated with the presence of PVTT and predicted a poor prognosis. Comparable results were achieved in our study. The expression of SERPINB2 was significantly lower in HCC tissues than in non-cancerous tissues, whereas the reverse was true for the expression of uPA and uPAR. In two patients with HCC and PVTT, the staining intensity of SERPINB2 reduced from normal to HCC and to PVTT tissues. However, the opposite trend was observed for uPAR. These findings further strengthen the ability of the uPA system to regulate HCC cell migration and invasion.
Given the potency of the uPA system in promoting invasion and metastasis in a wide variety of malignancies, targeting the uPA system is a potential strategy for the treatment of cancer [37, 46, 7577]. In the past, therapeutic agents and approaches have focused on regulating constituents of the uPA system or blocking their biological activity [7880]. In a previous study, recombinant SERPINB2 and SERPINB2 cDNAs were used to upregulate SERPINB2 expression [72, 8183]. In this study, we introduced a novel circPSD3 to enhance SERPINB2 expression, thereby inhibiting the uPA system. circRNAs are gradually being recognised as promising treatment agents by virtue of their high stability, low molecular weight, and low immunogenicity [13]. The manageable ectopic expression and in vitro synthesis of stable circRNAs have made circRNA-based therapies possible. For example, a circRNA packaged aptamer exhibited greater suppression of the NF-κB pathway than a linear packaged aptamer [84]. miRNA-122 is indispensable for the HCV life cycle by binding to the 5’UTR of HCV RNA. A synthesised circRNA sponge containing four miRNA-122 binding sites sequestered miRNA-122, thereby inhibiting protein synthesis with greater efficacy than Miravirsen [85]. Heterogeneous nuclear ribonucleoprotein L (hnRNPL), an RNA-binding protein, regulates alternative splicing by binding to short CA repeats of nuclear pre-mRNAs. An artificial circRNA containing 20–100 CA dinucleotides showed high affinity for hnRNPL and sequestered hnRNPL in the cytoplasm, resulted in alternative splicing events similar to those caused by siRNA-mediated hnRNPL depletion [86]. It is noteworthy that the aforementioned circRNA-based treatments have only been studied in cell lines or mouse models. Further researches are needed before these findings can be translated into the clinic.

Conclusions

circPSD3 is a circRNA that is involved in invasion and metastasis. Decreased circPSD3 in tumor tissues predicted a poor prognosis in patients with HCC after partial hepatectomy. TDP43 contributes to the biogenesis of circPSD3. Mechanistically, circPSD3 interacts with HDAC1, sequestering HDAC1 in the cytoplasm, thereby releasing the transcriptional repression of HDAC1 on SERPINB2. Elevated SERPINB2 inhibits the uPA system and mediates the inhibitory effect of circPSD3 on the regulation of the invasion and metastasis of HCC cells  (Fig. 8). Our findings provide novel insights into treatment strategies targeting the uPA system.

Acknowledgements

The authors thank Hongying Chen, Yan Wang, Xiangyi Ren, Mengli Zhu, Cong Li, Jingyao Zhang, Dan Li, and Liwen Qin (Research Core Facility of West China Hospital, Sichuan University, Chengdu, China) for their assistance with the cell and molecular experiments. We thank Zhenru Wu, Fei Chen, and Chunjuan Bao (Institute of Clinical Pathology, West China Hospital, Sichuan University) for performing the HE and IHC staining. We thank Yang Yang, Xijing Yang, and Xiaoting Chen (Animal Laboratory Center of West China Hospital of Sichuan University) for their assistance with the construction of the animal models.

Declarations

The use of clinical specimens was approved by the Biomedical Ethics Committee of West China Hospital (Approval number: 2022(1685)). All animal experiments were approved by the Animal Care and Use Committee of Sichuan University (Approval number: 20220224052).
All subjects have written informed consent.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global Cancer. Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global Cancer. Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
2.
Zurück zum Zitat Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.PubMedCrossRef Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.PubMedCrossRef
3.
Zurück zum Zitat Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and underlying etiologies from 1990 to 2015 at the Global, Regional, and National Level: results from the global burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–91.PubMedPubMedCentralCrossRef Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and underlying etiologies from 1990 to 2015 at the Global, Regional, and National Level: results from the global burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–91.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV patients treated with Direct-Acting Antiviral agents. Gastroenterology. 2017;153:996–1005e1.PubMedCrossRef Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV patients treated with Direct-Acting Antiviral agents. Gastroenterology. 2017;153:996–1005e1.PubMedCrossRef
5.
Zurück zum Zitat Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty Liver Disease demonstrates an exponential increase in burden of Disease. Hepatology. 2018;67:123–33.PubMedCrossRef Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty Liver Disease demonstrates an exponential increase in burden of Disease. Hepatology. 2018;67:123–33.PubMedCrossRef
7.
Zurück zum Zitat Yin J, Bo WT, Sun J, Xiang X, Lang JY, Zhong JH, Li LQ. New evidence and perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol. 2017;5:169–76.PubMedPubMedCentral Yin J, Bo WT, Sun J, Xiang X, Lang JY, Zhong JH, Li LQ. New evidence and perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol. 2017;5:169–76.PubMedPubMedCentral
8.
Zurück zum Zitat Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer. 2020;9:28–40.PubMedCrossRef Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer. 2020;9:28–40.PubMedCrossRef
9.
Zurück zum Zitat Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 1998;21:386–91.PubMedCrossRef Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 1998;21:386–91.PubMedCrossRef
10.
Zurück zum Zitat Huo L, Wei W, Yan Z, Lei Z, Xie Y, Gong R, Huang S, Jia N, Xia Y. Short-term and long-term outcomes of liver resection for HCC patients with portal vein Tumor thrombus. Cell Biosci. 2019;9:23.PubMedPubMedCentralCrossRef Huo L, Wei W, Yan Z, Lei Z, Xie Y, Gong R, Huang S, Jia N, Xia Y. Short-term and long-term outcomes of liver resection for HCC patients with portal vein Tumor thrombus. Cell Biosci. 2019;9:23.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938–43.PubMedCrossRef Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938–43.PubMedCrossRef
12.
Zurück zum Zitat Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20:675–91.PubMedCrossRef Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20:675–91.PubMedCrossRef
13.
Zurück zum Zitat Liu CX, Chen LL. Circular RNAs: characterization, cellular roles, and applications. Cell. 2022;185:2390.PubMedCrossRef Liu CX, Chen LL. Circular RNAs: characterization, cellular roles, and applications. Cell. 2022;185:2390.PubMedCrossRef
14.
Zurück zum Zitat Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21:475–90.PubMedCrossRef Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21:475–90.PubMedCrossRef
16.
Zurück zum Zitat Xu L, Zhang M, Zheng X, Yi P, Lan C, Xu M. The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143:17–27.PubMedCrossRef Xu L, Zhang M, Zheng X, Yi P, Lan C, Xu M. The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143:17–27.PubMedCrossRef
17.
Zurück zum Zitat Xu L, Feng X, Hao X, Wang P, Zhang Y, Zheng X, et al. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. J Exp Clin Cancer Res. 2019;38:98.PubMedPubMedCentralCrossRef Xu L, Feng X, Hao X, Wang P, Zhang Y, Zheng X, et al. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. J Exp Clin Cancer Res. 2019;38:98.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Hu ZQ, Zhou SL, Li J, Zhou ZJ, Wang PC, Xin HY, et al. Circular RNA sequencing identifies CircASAP1 as a Key Regulator in Hepatocellular Carcinoma Metastasis. Hepatology. 2020;72:906–22.PubMedCrossRef Hu ZQ, Zhou SL, Li J, Zhou ZJ, Wang PC, Xin HY, et al. Circular RNA sequencing identifies CircASAP1 as a Key Regulator in Hepatocellular Carcinoma Metastasis. Hepatology. 2020;72:906–22.PubMedCrossRef
19.
Zurück zum Zitat Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP. Burroughs AK A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20:325–39.PubMedCrossRef Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP. Burroughs AK A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20:325–39.PubMedCrossRef
20.
Zurück zum Zitat Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Guanghui D, Wenming C, Peijun W. Yuxiang Z Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the Tumor thrombi in the portal vein. Hepatogastroenterology. 2007;54:499–502.PubMed Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Guanghui D, Wenming C, Peijun W. Yuxiang Z Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the Tumor thrombi in the portal vein. Hepatogastroenterology. 2007;54:499–502.PubMed
21.
Zurück zum Zitat Zhang H, Ye J, Weng X, Liu F, He L, Zhou D, Liu Y. Comparative transcriptome analysis reveals that the extracellular matrix receptor interaction contributes to the venous metastases of hepatocellular carcinoma. Cancer Genet. 2015;208:482–91.PubMedCrossRef Zhang H, Ye J, Weng X, Liu F, He L, Zhou D, Liu Y. Comparative transcriptome analysis reveals that the extracellular matrix receptor interaction contributes to the venous metastases of hepatocellular carcinoma. Cancer Genet. 2015;208:482–91.PubMedCrossRef
22.
Zurück zum Zitat Liu S, Guo W, Shi J, Li N, Yu X, Xue J, et al. MicroRNA-135a contributes to the development of portal vein Tumor thrombus by promoting Metastasis in hepatocellular carcinoma. J Hepatol. 2012;56:389–96.PubMedCrossRef Liu S, Guo W, Shi J, Li N, Yu X, Xue J, et al. MicroRNA-135a contributes to the development of portal vein Tumor thrombus by promoting Metastasis in hepatocellular carcinoma. J Hepatol. 2012;56:389–96.PubMedCrossRef
23.
24.
Zurück zum Zitat Xu L, Wang P, Feng X, Tang J, Li L, Zheng X, et al. SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and Metastasis of hepatocellular carcinoma. Clin Sci (Lond). 2019;133:2085–105.PubMedCrossRef Xu L, Wang P, Feng X, Tang J, Li L, Zheng X, et al. SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and Metastasis of hepatocellular carcinoma. Clin Sci (Lond). 2019;133:2085–105.PubMedCrossRef
25.
Zurück zum Zitat Vinci M, Box C, Eccles SA. Three-dimensional (3D) Tumor spheroid invasion assay. J Vis Exp. 2015;e52686. Vinci M, Box C, Eccles SA. Three-dimensional (3D) Tumor spheroid invasion assay. J Vis Exp. 2015;e52686.
26.
Zurück zum Zitat Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, et al. Advances in establishment and analysis of three-dimensional Tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012;10:29.PubMedPubMedCentralCrossRef Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, et al. Advances in establishment and analysis of three-dimensional Tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012;10:29.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Ivascu A, Kubbies M. Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J Biomol Screen. 2006;11:922–32.PubMedCrossRef Ivascu A, Kubbies M. Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J Biomol Screen. 2006;11:922–32.PubMedCrossRef
28.
Zurück zum Zitat Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160:1125–34.PubMedCrossRef Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160:1125–34.PubMedCrossRef
29.
Zurück zum Zitat Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56:55–66.PubMedCrossRef Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56:55–66.PubMedCrossRef
30.
Zurück zum Zitat Ivanov A, Memczak S, Wyler E, Torti F, Porath HT, Orejuela MR, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015;10:170–7.PubMedCrossRef Ivanov A, Memczak S, Wyler E, Torti F, Porath HT, Orejuela MR, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015;10:170–7.PubMedCrossRef
31.
Zurück zum Zitat Doke AA, Jha SK, Shapeshifter. TDP-43: molecular mechanism of structural polymorphism, aggregation, phase separation and their modulators. Biophys Chem. 2023;295:106972.PubMedCrossRef Doke AA, Jha SK, Shapeshifter. TDP-43: molecular mechanism of structural polymorphism, aggregation, phase separation and their modulators. Biophys Chem. 2023;295:106972.PubMedCrossRef
32.
Zurück zum Zitat Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, et al. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 2013;58:182–91.PubMedCrossRef Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, et al. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 2013;58:182–91.PubMedCrossRef
33.
Zurück zum Zitat Guo F, Wang H, Jiang M, Yang Q, Xiang Q, Zhou H, et al. TDP-43 induces EMT and promotes hepatocellular carcinoma Metastasis via activating Wnt/β-catenin signaling pathway. Am J Cancer Res. 2020;10:3285–301.PubMedPubMedCentral Guo F, Wang H, Jiang M, Yang Q, Xiang Q, Zhou H, et al. TDP-43 induces EMT and promotes hepatocellular carcinoma Metastasis via activating Wnt/β-catenin signaling pathway. Am J Cancer Res. 2020;10:3285–301.PubMedPubMedCentral
34.
Zurück zum Zitat Liu BW, Wang XY, Cao JL, Chen LL, Wang YL, Zhao BQ, Zhou J. Shen ZF TDP-43 upregulates lipid metabolism modulator ABHD2 to suppress apoptosis in hepatocellular carcinoma. Commun Biol. 2022;5:816.PubMedPubMedCentralCrossRef Liu BW, Wang XY, Cao JL, Chen LL, Wang YL, Zhao BQ, Zhou J. Shen ZF TDP-43 upregulates lipid metabolism modulator ABHD2 to suppress apoptosis in hepatocellular carcinoma. Commun Biol. 2022;5:816.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Cochran BJ, Gunawardhana LP, Vine KL, Lee JA, Lobov S, Ranson M. The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity. BMC Biotechnol. 2009;9:43.PubMedPubMedCentralCrossRef Cochran BJ, Gunawardhana LP, Vine KL, Lee JA, Lobov S, Ranson M. The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity. BMC Biotechnol. 2009;9:43.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Croucher DR, Saunders DN, Lobov S, Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer. 2008;8:535–45.PubMedCrossRef Croucher DR, Saunders DN, Lobov S, Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer. 2008;8:535–45.PubMedCrossRef
37.
Zurück zum Zitat Su SC, Lin CW, Yang WE, Fan WL, Yang SF. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Ther Targets. 2016;20:551–66.PubMedCrossRef Su SC, Lin CW, Yang WE, Fan WL, Yang SF. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Ther Targets. 2016;20:551–66.PubMedCrossRef
38.
Zurück zum Zitat Zhou L, Jin Y, Cui QC, Jin KM, Zhou WX, Xing BC. Low expression of PAI-2 as a novel marker of portal vein Tumor Thrombosis and poor prognosis in hepatocellular carcinoma. World J Surg. 2013;37:608–13.PubMedCrossRef Zhou L, Jin Y, Cui QC, Jin KM, Zhou WX, Xing BC. Low expression of PAI-2 as a novel marker of portal vein Tumor Thrombosis and poor prognosis in hepatocellular carcinoma. World J Surg. 2013;37:608–13.PubMedCrossRef
39.
Zurück zum Zitat Zhou L, Hayashi Y, Itoh T, Wang W, Rui J, Itoh H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and – 2 in hepatocellular carcinoma. Pathol Int. 2000;50:392–7.PubMedCrossRef Zhou L, Hayashi Y, Itoh T, Wang W, Rui J, Itoh H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and – 2 in hepatocellular carcinoma. Pathol Int. 2000;50:392–7.PubMedCrossRef
40.
Zurück zum Zitat De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res. 1998;58:2234–9.PubMed De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res. 1998;58:2234–9.PubMed
41.
Zurück zum Zitat Du J, Lan T, Liao H, Feng X, Chen X, Liao W, et al. CircNFIB inhibits Tumor growth and Metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma. Mol Cancer. 2022;21:18.PubMedPubMedCentralCrossRef Du J, Lan T, Liao H, Feng X, Chen X, Liao W, et al. CircNFIB inhibits Tumor growth and Metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma. Mol Cancer. 2022;21:18.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Hong X, Li Q, Li J, Chen K, He Q, Zhao Y, et al. CircIPO7 promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by facilitating YBX1 Nuclear localization. Clin Cancer Res. 2022;28:4521–35.PubMedCrossRef Hong X, Li Q, Li J, Chen K, He Q, Zhao Y, et al. CircIPO7 promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by facilitating YBX1 Nuclear localization. Clin Cancer Res. 2022;28:4521–35.PubMedCrossRef
43.
Zurück zum Zitat Kurdistani SK, Tavazoie S, Grunstein M. Mapping global histone acetylation patterns to gene expression. Cell. 2004;117:721–33.PubMedCrossRef Kurdistani SK, Tavazoie S, Grunstein M. Mapping global histone acetylation patterns to gene expression. Cell. 2004;117:721–33.PubMedCrossRef
44.
Zurück zum Zitat Macaluso M, Montanari M, Marshall CM, Gambone AJ, Tosi GM, Giordano A, Massaro-Giordano M. Cytoplasmic and nuclear interaction between rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells. Cell Death Differ. 2006;13:1515–22.PubMedCrossRef Macaluso M, Montanari M, Marshall CM, Gambone AJ, Tosi GM, Giordano A, Massaro-Giordano M. Cytoplasmic and nuclear interaction between rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells. Cell Death Differ. 2006;13:1515–22.PubMedCrossRef
45.
Zurück zum Zitat Pucci S, Zonetti MJ, Fisco T, Polidoro C, Bocchinfuso G, Palleschi A, Novelli G, Spagnoli LG. Mazzarelli P carnitine palmitoyl transferase-1A (CPT1A): a new Tumor specific target in human Breast cancer. Oncotarget. 2016;7:19982–96.PubMedPubMedCentralCrossRef Pucci S, Zonetti MJ, Fisco T, Polidoro C, Bocchinfuso G, Palleschi A, Novelli G, Spagnoli LG. Mazzarelli P carnitine palmitoyl transferase-1A (CPT1A): a new Tumor specific target in human Breast cancer. Oncotarget. 2016;7:19982–96.PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Mekkawy AH, Pourgholami MH. Morris DL involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev. 2014;34:918–56.PubMedCrossRef Mekkawy AH, Pourgholami MH. Morris DL involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev. 2014;34:918–56.PubMedCrossRef
47.
Zurück zum Zitat Xie X, Li H, Gao C, Lai Y, Liang J, Chen Z, et al. Downregulation of circular RNA circPSD3 promotes Metastasis by modulating FBXW7 expression in Clear Cell Renal Cell Carcinoma. J Oncol. 2022;2022:5084631.PubMedPubMedCentralCrossRef Xie X, Li H, Gao C, Lai Y, Liang J, Chen Z, et al. Downregulation of circular RNA circPSD3 promotes Metastasis by modulating FBXW7 expression in Clear Cell Renal Cell Carcinoma. J Oncol. 2022;2022:5084631.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Zhu J, Wang Y, Yang C, Feng Z, Huang Y, Liu P, Chen F, Deng Z. circ-PSD3 promoted proliferation and invasion of papillary thyroid cancer cells via regulating the miR-7-5p/METTL7B axis. J Recept Signal Transduct Res. 2022;42:251–60.PubMedCrossRef Zhu J, Wang Y, Yang C, Feng Z, Huang Y, Liu P, Chen F, Deng Z. circ-PSD3 promoted proliferation and invasion of papillary thyroid cancer cells via regulating the miR-7-5p/METTL7B axis. J Recept Signal Transduct Res. 2022;42:251–60.PubMedCrossRef
49.
Zurück zum Zitat Bu FT, Zhu Y, Chen X, Wang A, Zhang YF, You HM, et al. Circular RNA circPSD3 alleviates hepatic fibrogenesis by regulating the miR-92b-3p/Smad7 axis. Mol Ther Nucleic Acids. 2021;23:847–62.PubMedPubMedCentralCrossRef Bu FT, Zhu Y, Chen X, Wang A, Zhang YF, You HM, et al. Circular RNA circPSD3 alleviates hepatic fibrogenesis by regulating the miR-92b-3p/Smad7 axis. Mol Ther Nucleic Acids. 2021;23:847–62.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Chen TC, Tallo-Parra M, Cao QM, Kadener S, Böttcher R, Pérez-Vilaró G, et al. Host-derived circular RNAs display proviral activities in Hepatitis C virus-infected cells. PLoS Pathog. 2020;16:e1008346.PubMedPubMedCentralCrossRef Chen TC, Tallo-Parra M, Cao QM, Kadener S, Böttcher R, Pérez-Vilaró G, et al. Host-derived circular RNAs display proviral activities in Hepatitis C virus-infected cells. PLoS Pathog. 2020;16:e1008346.PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Yu J, Xu QG, Wang ZG, Yang Y, Zhang L, Ma JZ, Sun SH, Yang F. Zhou WP Circular RNA cSMARCA5 inhibits growth and Metastasis in hepatocellular carcinoma. J Hepatol. 2018;68:1214–27.PubMedCrossRef Yu J, Xu QG, Wang ZG, Yang Y, Zhang L, Ma JZ, Sun SH, Yang F. Zhou WP Circular RNA cSMARCA5 inhibits growth and Metastasis in hepatocellular carcinoma. J Hepatol. 2018;68:1214–27.PubMedCrossRef
52.
Zurück zum Zitat Chioccarelli T, Falco G, Cappetta D, De Angelis A, Roberto L, Addeo M, et al. FUS driven circCNOT6L biogenesis in mouse and human spermatozoa supports zygote development. Cell Mol Life Sci. 2021;79:50.PubMedPubMedCentralCrossRef Chioccarelli T, Falco G, Cappetta D, De Angelis A, Roberto L, Addeo M, et al. FUS driven circCNOT6L biogenesis in mouse and human spermatozoa supports zygote development. Cell Mol Life Sci. 2021;79:50.PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Wang R, Zhang S, Chen X, Li N, Li J, Jia R, Pan Y, Liang H. EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes Glioblastoma Multiforme cell tumorigenesis. Mol Cancer. 2018;17:166.PubMedPubMedCentralCrossRef Wang R, Zhang S, Chen X, Li N, Li J, Jia R, Pan Y, Liang H. EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes Glioblastoma Multiforme cell tumorigenesis. Mol Cancer. 2018;17:166.PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Liu Y, Song J, Zhang H, Liao Z, Liu F, Su C, et al. EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway. J Exp Clin Cancer Res. 2022;41:164.PubMedCrossRef Liu Y, Song J, Zhang H, Liao Z, Liu F, Su C, et al. EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway. J Exp Clin Cancer Res. 2022;41:164.PubMedCrossRef
55.
Zurück zum Zitat de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, et al. TDP-43 proteinopathies: a new wave of neurodegenerative Diseases. J Neurol Neurosurg Psychiatry. 2020;92:86–95.PubMedCrossRef de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, et al. TDP-43 proteinopathies: a new wave of neurodegenerative Diseases. J Neurol Neurosurg Psychiatry. 2020;92:86–95.PubMedCrossRef
56.
Zurück zum Zitat Guo L, Ke H, Zhang H, Zou L, Yang Q, Lu X, Zhao L, Jiao B. TDP43 promotes stemness of Breast cancer stem cells through CD44 variant splicing isoforms. Cell Death Dis. 2022;13:428.PubMedPubMedCentralCrossRef Guo L, Ke H, Zhang H, Zou L, Yang Q, Lu X, Zhao L, Jiao B. TDP43 promotes stemness of Breast cancer stem cells through CD44 variant splicing isoforms. Cell Death Dis. 2022;13:428.PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Ke H, Zhao L, Zhang H, Feng X, Xu H, Hao J, et al. Loss of TDP43 inhibits progression of triple-negative Breast cancer in coordination with SRSF3. Proc Natl Acad Sci U S A. 2018;115:E3426–e35.PubMedPubMedCentralCrossRef Ke H, Zhao L, Zhang H, Feng X, Xu H, Hao J, et al. Loss of TDP43 inhibits progression of triple-negative Breast cancer in coordination with SRSF3. Proc Natl Acad Sci U S A. 2018;115:E3426–e35.PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Chen X, Fan Z, McGee W, Chen M, Kong R, Wen P, et al. TDP-43 regulates cancer-associated microRNAs. Protein Cell. 2018;9:848–66.PubMedCrossRef Chen X, Fan Z, McGee W, Chen M, Kong R, Wen P, et al. TDP-43 regulates cancer-associated microRNAs. Protein Cell. 2018;9:848–66.PubMedCrossRef
59.
Zurück zum Zitat Zeng Q, Cao K, Liu R, Huang J, Xia K, Tang J, et al. Identification of TDP-43 as an oncogene in Melanoma and its function during Melanoma pathogenesis. Cancer Biol Ther. 2017;18:8–15.PubMedCrossRef Zeng Q, Cao K, Liu R, Huang J, Xia K, Tang J, et al. Identification of TDP-43 as an oncogene in Melanoma and its function during Melanoma pathogenesis. Cancer Biol Ther. 2017;18:8–15.PubMedCrossRef
60.
Zurück zum Zitat Guo SK, Nan F, Liu CX, Yang L, Chen LL. Mapping circular RNA structures in living cells by SHAPE-MaP. Methods. 2021;196:47–55.PubMedCrossRef Guo SK, Nan F, Liu CX, Yang L, Chen LL. Mapping circular RNA structures in living cells by SHAPE-MaP. Methods. 2021;196:47–55.PubMedCrossRef
61.
Zurück zum Zitat Liu CX, Li X, Nan F, Jiang S, Gao X, Guo SK, et al. Structure and degradation of circular RNAs regulate PKR activation in Innate Immunity. Cell. 2019;177:865–80e21.PubMedCrossRef Liu CX, Li X, Nan F, Jiang S, Gao X, Guo SK, et al. Structure and degradation of circular RNAs regulate PKR activation in Innate Immunity. Cell. 2019;177:865–80e21.PubMedCrossRef
62.
Zurück zum Zitat Ler SY, Leung CH, Khin LW, Lu GD, Salto-Tellez M, Hartman M, Iau PT, Yap CT. Hooi SC HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a southeast Asian population. Oncol Rep. 2015;34:2238–50.PubMedPubMedCentralCrossRef Ler SY, Leung CH, Khin LW, Lu GD, Salto-Tellez M, Hartman M, Iau PT, Yap CT. Hooi SC HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a southeast Asian population. Oncol Rep. 2015;34:2238–50.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, Maehara Y. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 2007;72:69–74.PubMedCrossRef Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, Maehara Y. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 2007;72:69–74.PubMedCrossRef
64.
Zurück zum Zitat Zhao B, Ke K, Wang Y, Wang F, Shi Y, Zheng X, Yang X, Liu X, Liu J. HIF-1α and HDAC1 mediated regulation of FAM99A-miR92a signaling contributes to hypoxia induced HCC Metastasis. Signal Transduct Target Ther. 2020;5:118.PubMedPubMedCentralCrossRef Zhao B, Ke K, Wang Y, Wang F, Shi Y, Zheng X, Yang X, Liu X, Liu J. HIF-1α and HDAC1 mediated regulation of FAM99A-miR92a signaling contributes to hypoxia induced HCC Metastasis. Signal Transduct Target Ther. 2020;5:118.PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M. Rømer J Plasminogen activation and cancer. Thromb Haemost. 2005;93:676–81.PubMedCrossRef Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M. Rømer J Plasminogen activation and cancer. Thromb Haemost. 2005;93:676–81.PubMedCrossRef
66.
Zurück zum Zitat Baldini E, Sorrenti S, D’Armiento E, Di Matteo FM, Catania A, Ulisse S. The urokinase plasminogen activating system in thyroid cancer: clinical implications. G Chir. 2012;33:305–10.PubMed Baldini E, Sorrenti S, D’Armiento E, Di Matteo FM, Catania A, Ulisse S. The urokinase plasminogen activating system in thyroid cancer: clinical implications. G Chir. 2012;33:305–10.PubMed
67.
Zurück zum Zitat O’Rourke J, Jiang X, Hao Z, Cone RE. Hand AR distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature. J Neurosci Res. 2005;79:727–33.PubMedCrossRef O’Rourke J, Jiang X, Hao Z, Cone RE. Hand AR distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature. J Neurosci Res. 2005;79:727–33.PubMedCrossRef
68.
Zurück zum Zitat Ranson M, Andronicos NM. Plasminogen binding and cancer: promises and pitfalls. Front Biosci. 2003;8:294–304.CrossRef Ranson M, Andronicos NM. Plasminogen binding and cancer: promises and pitfalls. Front Biosci. 2003;8:294–304.CrossRef
69.
Zurück zum Zitat Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des. 2003;9:1499–528.PubMedCrossRef Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des. 2003;9:1499–528.PubMedCrossRef
70.
Zurück zum Zitat Behrendt N, List K, Andreasen PA. Danø K the pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J. 2003;371:277–87.PubMedPubMedCentralCrossRef Behrendt N, List K, Andreasen PA. Danø K the pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J. 2003;371:277–87.PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Kruithof EK, Baker MS. Bunn CL Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood. 1995;86:4007–24.PubMedCrossRef Kruithof EK, Baker MS. Bunn CL Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood. 1995;86:4007–24.PubMedCrossRef
73.
Zurück zum Zitat Al-Ejeh F, Croucher D, Ranson M. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines. Exp Cell Res. 2004;297:259–71.PubMedCrossRef Al-Ejeh F, Croucher D, Ranson M. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines. Exp Cell Res. 2004;297:259–71.PubMedCrossRef
74.
Zurück zum Zitat Lillis AP, Mikhailenko I, Strickland DK. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J Thromb Haemost. 2005;3:1884–93.PubMedCrossRef Lillis AP, Mikhailenko I, Strickland DK. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J Thromb Haemost. 2005;3:1884–93.PubMedCrossRef
75.
Zurück zum Zitat Tao P, Gao L, Li H, Wang B, Li X, Zhang Y, Chen H. Prognostic role of urokinase plasminogen activator in hepatocellular carcinoma: a protocol for systematic review and meta analysis. Med (Baltim). 2020;99:e23841.CrossRef Tao P, Gao L, Li H, Wang B, Li X, Zhang Y, Chen H. Prognostic role of urokinase plasminogen activator in hepatocellular carcinoma: a protocol for systematic review and meta analysis. Med (Baltim). 2020;99:e23841.CrossRef
76.
Zurück zum Zitat Salvi A, Arici B, De Petro G, Barlati S. Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther. 2004;3:671–8.PubMedCrossRef Salvi A, Arici B, De Petro G, Barlati S. Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther. 2004;3:671–8.PubMedCrossRef
77.
Zurück zum Zitat Niu FY, Jin C, Ma L, Shi YX, Li XS, Jiang P, Gao S, Lin JR. Song Y urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma. J Gastrointest Oncol. 2021;12:1851–59.PubMedPubMedCentralCrossRef Niu FY, Jin C, Ma L, Shi YX, Li XS, Jiang P, Gao S, Lin JR. Song Y urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma. J Gastrointest Oncol. 2021;12:1851–59.PubMedPubMedCentralCrossRef
78.
Zurück zum Zitat Ulisse S, Baldini E, Sorrenti S, D’Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 2009;9:32–71.PubMedCrossRef Ulisse S, Baldini E, Sorrenti S, D’Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 2009;9:32–71.PubMedCrossRef
79.
Zurück zum Zitat Mekkawy AH, Morris DL. Pourgholami MH Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 2009;5:1487–99.PubMedCrossRef Mekkawy AH, Morris DL. Pourgholami MH Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 2009;5:1487–99.PubMedCrossRef
80.
Zurück zum Zitat Salvi A, Conde I, Abeni E, Arici B, Grossi I, Specchia C, Portolani N, Barlati S. De Petro G effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer. 2013;12:162.PubMedPubMedCentralCrossRef Salvi A, Conde I, Abeni E, Arici B, Grossi I, Specchia C, Portolani N, Barlati S. De Petro G effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer. 2013;12:162.PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Fernández-Soria V, Lleonart ME, Diaz-Fuertes M, Villuendas R, Sánchez-Prieto R, Fabra A. Ramón YCS Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a Tumor suppressor effect. Int J Oncol. 2006;28:143–8.PubMed Fernández-Soria V, Lleonart ME, Diaz-Fuertes M, Villuendas R, Sánchez-Prieto R, Fabra A. Ramón YCS Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a Tumor suppressor effect. Int J Oncol. 2006;28:143–8.PubMed
82.
Zurück zum Zitat Guan M, Jiang H, Xu C, Xu R, Chen Z, Lu Y. Adenovirus-mediated PEDF expression inhibits Prostate cancer cell growth and results in augmented expression of PAI-2. Cancer Biol Ther. 2007;6:419–25.PubMedCrossRef Guan M, Jiang H, Xu C, Xu R, Chen Z, Lu Y. Adenovirus-mediated PEDF expression inhibits Prostate cancer cell growth and results in augmented expression of PAI-2. Cancer Biol Ther. 2007;6:419–25.PubMedCrossRef
83.
Zurück zum Zitat Shimizu T, Sato K, Suzuki T, Tachibana K, Takeda K. Induction of plasminogen activator inhibitor-2 is associated with suppression of invasive activity in TPA-mediated differentiation of human Prostate cancer cells. Biochem Biophys Res Commun. 2003;309:267–71.PubMedCrossRef Shimizu T, Sato K, Suzuki T, Tachibana K, Takeda K. Induction of plasminogen activator inhibitor-2 is associated with suppression of invasive activity in TPA-mediated differentiation of human Prostate cancer cells. Biochem Biophys Res Commun. 2003;309:267–71.PubMedCrossRef
84.
Zurück zum Zitat Litke JL, Jaffrey SR. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. Nat Biotechnol. 2019;37:667–75.PubMedCentralCrossRef Litke JL, Jaffrey SR. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. Nat Biotechnol. 2019;37:667–75.PubMedCentralCrossRef
85.
Zurück zum Zitat Jost I, Shalamova LA, Gerresheim GK, Niepmann M, Bindereif A, Rossbach O. Functional sequestration of microRNA-122 from Hepatitis C Virus by circular RNA sponges. RNA Biol. 2018;15:1032–39.PubMedPubMedCentral Jost I, Shalamova LA, Gerresheim GK, Niepmann M, Bindereif A, Rossbach O. Functional sequestration of microRNA-122 from Hepatitis C Virus by circular RNA sponges. RNA Biol. 2018;15:1032–39.PubMedPubMedCentral
86.
Zurück zum Zitat Schreiner S, Didio A, Hung LH, Bindereif A. Design and application of circular RNAs with protein-sponge function. Nucleic Acids Res. 2020;48:12326–35.PubMedPubMedCentralCrossRef Schreiner S, Didio A, Hung LH, Bindereif A. Design and application of circular RNAs with protein-sponge function. Nucleic Acids Res. 2020;48:12326–35.PubMedPubMedCentralCrossRef
Metadaten
Titel
circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma
verfasst von
Liangliang Xu
Peng Wang
Li Li
Lian Li
Yang Huang
Yanfang Zhang
Xiaobo Zheng
Pengsheng Yi
Ming Zhang
Mingqing Xu
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
Molecular Cancer / Ausgabe 1/2023
Elektronische ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-023-01882-z

Weitere Artikel der Ausgabe 1/2023

Molecular Cancer 1/2023 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.